2024-03-22 15:49:45 ET
Summary
- GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology.
- The fund's historical performance has been poor amid volatile stock prices for underlying holdings.
- Genomics may be the future, but still missing a blockbuster application to drive a wave of bullish momentum into the segment.
The Global X Genomics & Biotechnology ETF ( GNOM ) offers exposure to companies innovating in the field of genomic science covering techniques such as gene editing, DNA sequencing, and genetic therapy. The attraction here is an expectation that genomics will revolutionize medicine through tailored treatments that target identified proteins that cause underlying disorders. ...
Read the full article on Seeking Alpha
For further details see:
GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment